Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT6 | P42226 | 1/20 | 0.50 |
| ▸ | PTK2 | Q05397 | 10/20 | 0.45 |
| ▸ | SYK | P43405 | 2/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15524487 | 0.93 | STAT6 (0.44) | STAT6PTK2SYK | |
| SCHEMBL15524430 | 0.91 | STAT6 (0.46) | STAT6PTK2SYKJAK2 | |
| SCHEMBL15524674 | 0.90 | FLT4 (0.47) | STAT6PTK2SYKFLT4KDR | |
| SCHEMBL15524377 | 0.88 | CAMK2D (0.43) | STAT6PTK2SYKBTKJAK2 | |
| SCHEMBL12478260 | 0.88 | PTK2 (0.54) | STAT6PTK2FLT4KDR | |
| SCHEMBL15524121 | 0.87 | SYK (0.51) | STAT6SYK | |
| SCHEMBL15524600 | 0.85 | FLT4 (0.48) | JAK2FLT4KDR | |
| SCHEMBL15524390 | 0.84 | JAK3 (0.42) | STAT6PTK2SYKJAK2 | |
| SCHEMBL15524294 | 0.84 | PTK2 (0.50) | STAT6PTK2FLT4KDR | |
| SCHEMBL12479026 | 0.83 | PTK2 (0.51) | STAT6PTK2FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| US-20140080798-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-20 | — | — | US | disclosed |
| US-20080152911-A1 | TEMPLATED METAL PARTICLES AND METHODS OF MAKING | 3M INNOVATIVE PROPERTIES COMPANY | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225377-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | STAT6 4087/4885PTK2 240/4885SYK 126/4885 |
| US-20140080798-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | STAT6 3580/4885PTK2 260/4885SYK 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.